pubmed-article:20063133 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C0220615 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C0205103 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
pubmed-article:20063133 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
pubmed-article:20063133 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:20063133 | pubmed:dateCreated | 2010-3-18 | lld:pubmed |
pubmed-article:20063133 | pubmed:abstractText | We prospectively compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy as a post-remission therapy in a multicenter trial (JALSG AML97) of adult patients with intermediate or poor risk acute myeloid leukemia (AML). Of 503 patients aged 15-50 years old registered between December 1997 and July 2001, 392 achieved complete remission (CR). CR patients classified in the intermediate or poor risk group using a new scoring system were tissue typed. Seventy-three with and 92 without an HLA-identical sibling were assigned to the donor and no-donor groups. Of 73 patients in the donor group, 38 (52%) received allo-HSCT during CR1 and 17 (23%) after relapse. Intention-to-treat analysis revealed that the relapse incidence was reduced in the donor group (52 vs. 77%; p = 0.008), and the disease-free survival (DFS) improved (39 vs. 19%; p = 0.016), but overall survival (OS) was not significantly different (46 vs. 29%; p = 0.088). The OS benefit was seen in the patients aged 36-50 years old (49 vs. 24%; p = 0.031), suggesting an advantage of allo-HSCT among older patients with leukemia that is more resistant to chemotherapy than that among younger patients. | lld:pubmed |
pubmed-article:20063133 | pubmed:language | eng | lld:pubmed |
pubmed-article:20063133 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20063133 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20063133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20063133 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20063133 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20063133 | pubmed:month | Mar | lld:pubmed |
pubmed-article:20063133 | pubmed:issn | 1865-3774 | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:YagasakiFumih... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:AsouNorioN | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:MitaniKinukoK | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:OhnoRyuzoR | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:SakamakiHisas... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:OgawaYoshiaki... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:MiyawakiShuic... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:EmiNobuhikoN | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:HondaSumihisa... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:KishimotoYuji... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:MiyazakiYasus... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:OhtakeShigeki... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:TakahashiMasa... | lld:pubmed |
pubmed-article:20063133 | pubmed:author | pubmed-author:MatsudaShinS | lld:pubmed |
pubmed-article:20063133 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20063133 | pubmed:volume | 91 | lld:pubmed |
pubmed-article:20063133 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20063133 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20063133 | pubmed:pagination | 284-92 | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:meshHeading | pubmed-meshheading:20063133... | lld:pubmed |
pubmed-article:20063133 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20063133 | pubmed:articleTitle | Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. | lld:pubmed |
pubmed-article:20063133 | pubmed:affiliation | Division of Hematology, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. sakamaki-h@cick.jp | lld:pubmed |
pubmed-article:20063133 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20063133 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:20063133 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:20063133 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:20063133 | pubmed:publicationType | Multicenter Study | lld:pubmed |